VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Rizvi on Pseudo-Progression in Lung Cancer

Naiyer A. Rizvi, MD
Published: Monday, Jan 06, 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Rizvi says in a small number of patients that are treated with immunotherapy, early scans may show what looks to be signs of tumor growth. However, this may be a delayed benefit of the treatment or tumor inflammation as T cells become activated.

This phenomenon occurs in less than 10% of the patients, Rizvi says. Physicians should consider the patient’s well being in addition to scans in order to make a decision.
 
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Rizvi says in a small number of patients that are treated with immunotherapy, early scans may show what looks to be signs of tumor growth. However, this may be a delayed benefit of the treatment or tumor inflammation as T cells become activated.

This phenomenon occurs in less than 10% of the patients, Rizvi says. Physicians should consider the patient’s well being in addition to scans in order to make a decision.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x